Print  |  Close

Clinical Trial Search Results

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.

All Clinical Trials

Records 1 - 610 of 610
1.
(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
Cancer Type
Leukemia
NCI ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
2.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT05186753
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03800693
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
9-ING-41 in Patients With Advanced Cancers
Cancer Type
Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCI ID
NCT03678883
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCI ID
NCT05086692
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Cancer Type
Head and Neck Cancer
NCI ID
NCT04534205
Protocol IDs
BNT113-01
NCI-2021-03177
2020-001400-41
7.
A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04115631
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04505826
Protocol IDs
OP-1250-001
NCI-2020-13877
9.
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
Cancer Type
Colon/Rectal Cancer, Lung Cancer
NCI ID
NCT05397171
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
10.
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Cancer Type
Lung Cancer
NCI ID
NCT05120349
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT02954094
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Piedmont Hospital - Atlanta
Atlanta
12.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT01351545
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT00078598
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
14.
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT01630733
Protocol IDs
TV1011-LC-303
2012-002447-14
15.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
16.
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Cancer Type
Colon/Rectal Cancer, Ovarian Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer
NCI ID
NCT05360680
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03978689
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
18.
A Phase 1 Study of Engineered Donor Grafts (OrcaGraft/Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03802695
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
19.
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Cancer Type
Gynecologic Cancers, Lung Cancer, Primary Peritoneal Cancer
NCI ID
NCT05199272
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Cancer Type
Breast Cancer, Cervical Cancer, Gynecologic Cancers, Head and Neck Cancer, Ovarian Cancer
NCI ID
NCT04682431
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT03420183
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Cancer Type
Lung Cancer
NCI ID
NCT05060016
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Cancer Type
Leukemia
NCI ID
Protocol IDs
NCT01980875
24.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Kidney Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
25.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Head and Neck Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
26.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Melanoma
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
27.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Ovarian Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
28.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Adrenal Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
29.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Bladder Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
30.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Solid Tumor
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
31.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Mesothelioma
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
32.
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
NCT02339571
Protocol IDs
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
A Phase III Double Blind Study On The Efficacy of Topical Aloe Vera Gel on Irradiated Breast Tissue
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
34.
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Cancer Type
Colon/Rectal Cancer
NCI ID
Protocol IDs
NCT02563002
35.
A Phase III, Single-arm, Open Label, Single Study of Topical Application of a 2 Step Radiaderm Advanced Skincare System containing LactokineTM Fluid on Radiation Dermatitis in Breast Cancer Patients Treated with Adjuvant Whole Breast Radiation Therapy
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
36.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCI ID
Protocol IDs
AMG 011 20170758
37.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCI ID
Protocol IDs
AMG 011 20170758
38.
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and other Patients
Cancer Type
Multiple Primaries
NCI ID
Protocol IDs
39.
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer
Cancer Type
Multiple Primaries
NCI ID
Protocol IDs
40.
A Registry of Cesium-131 Brachytherapy Plus Sub- lobar Resection for Early Stage Lung Cancer
Cancer Type
Lung Cancer
NCI ID
Protocol IDs
41.
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04409301
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
42.
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT04035434
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
43.
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Cancer Type
Breast Cancer
NCI ID
NCT00781612
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
44.
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCI ID
NCT03374085
Protocol IDs
Treatment Sites (1)
Emory Clinic
Atlanta
45.
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type
Leukemia
NCI ID
NCT05482971
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
46.
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Cancer Type
Breast Cancer
NCI ID
NCT04873362
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
47.
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Cancer Type
Breast Cancer
NCI ID
NCT04961996
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
48.
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04546009
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
49.
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04191499
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
50.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04712097
Protocol IDs
GO42909
NCI-2021-09247
2020-005239-53
51.
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors that Cannot be Removed by Surgery
Cancer Type
Unknown Primary
NCI ID
NCT04195399
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
52.
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Cancer Type
Germ Cell Tumor, Gestational trophoblastic disease, Testicular Cancer, Unknown Primary
NCI ID
NCT04684368
Protocol IDs
ACNS2021
ACNS2021
NCI-2020-13175
53.
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Cancer Type
Bone Tumor
NCI ID
NCT03706365
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
54.
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03767244
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
55.
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCI ID
NCT04513925
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
56.
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04620330
Protocol IDs
VS-6766-202
NCI-2021-01997
57.
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04586231
Protocol IDs
6482-011
MK-6482-011
NCI-2020-11420
2020-002075-35
58.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03571568
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
59.
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT03400332
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
60.
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCI ID
NCT04943900
Protocol IDs
CA102-003
NCI-2021-09090
61.
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04404660
Protocol IDs
FELIX (AUTO1-AL1)
AUTO1-AL1
NCI-2020-04370
2019-001937-16
62.
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which has Spread to the Lymph Nodes (The INSPIRE Study)
Cancer Type
Bladder Cancer
NCI ID
NCT04216290
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
63.
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCI ID
NCT04322318
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
64.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
65.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCI ID
NCT05091346
Protocol IDs
E7386-G000-201
NCI-2022-02226
2021-001568-10
KEYNOTE-C83
66.
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT04607421
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
67.
A Study of Engineered Donor Grafts (Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT04013685
Protocol IDs
TRGFT-201
NCI-2019-08529
68.
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04083976
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
69.
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04172675
Protocol IDs
CR108699
NCI-2020-00674
42756493BLC2003
2019-002449-39
70.
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04764474
Protocol IDs
2020-306-GLOB1
NCI-2021-03247
71.
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04762602
Protocol IDs
2020-306-GLOB2
NCI-2021-01982
72.
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type
Unknown Primary
NCI ID
NCT05263999
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
73.
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05347485
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
74.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04133636
Protocol IDs
CR108581
2018-004124-10
68284528MMY2003
NCI-2019-07363
75.
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05241834
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
76.
A Study of LOXO-435 in Patients With Cancer With a Change in a Gene Called FGFR3
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05614739
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
77.
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Cancer Type
Breast Cancer, Solid Tumor, Unknown Primary
NCI ID
NCT05307705
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
78.
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04188548
Protocol IDs
17502
2019-003581-41
J2J-MC-JZLA
NCI-2020-06404
79.
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT03215030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
80.
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Cancer Type
Bone Tumor
NCI ID
NCT04100018
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
81.
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
82.
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04736706
Protocol IDs
6482-012
MK-6482-012
NCI-2021-05629
2020-002216-52
83.
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Cancer Type
Lymphoma, Neuroblastoma
NCI ID
NCT02332668
Protocol IDs
3475-051
NCI-2015-00528
2014-002950-38
84.
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Cancer Type
Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer
NCI ID
NCT02922764
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
85.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT05487170
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
86.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
87.
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type
Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT04211337
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
88.
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type
Leukemia
NCI ID
NCT04065399
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
89.
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT02716116
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
90.
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04776018
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
91.
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05050097
Protocol IDs
CR108946
NCI-2021-13605
2020-004502-55
64407564MMY1004
92.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
93.
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
Cancer Type
Neuroendocrine Tumor, Prostate Cancer , Unknown Primary
NCI ID
NCT04702737
Protocol IDs
20200040
NCI-2021-08862
94.
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT05083169
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
95.
A Study of the Drugs Selumetinib versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03871257
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
96.
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT04166409
Protocol IDs
ACNS1833
ACNS1833
NCI-2019-07600
97.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCI ID
NCT02817633
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
98.
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05132582
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
99.
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04539938
Protocol IDs
SGNTUC-025
NCI-2020-08177
100.
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03975647
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
101.
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Cancer Type
Multiple Myeloma
NCI ID
NCT04123418
Protocol IDs
CWVT078A12101
NCI-2021-09189
102.
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Cancer Type
Breast Cancer, Lung Cancer
NCI ID
NCT03845166
Protocol IDs
XL092-001
NCI-2019-03738
103.
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Cancer Type
Head and Neck Cancer
NCI ID
NCT03752398
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
104.
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Cancer Type
Cervical Cancer
NCI ID
NCT05032040
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
105.
A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05377996
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
106.
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Cancer Type
Lung Cancer, Pancreatic Cancer
NCI ID
NCT02912949
Protocol IDs
MCLA-128-CL01
NCI-2019-06025
2014-003277-42
107.
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioma with Elevated Mutational Burden
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04145115
Protocol IDs
A071702
A071702
NCI-2019-07242
108.
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Cancer Type
Melanoma, Unknown Primary
NCI ID
NCT05002569
Protocol IDs
CA224-098
NCI-2022-02119
2021-001641-13
109.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Lung Cancer, Solid Tumor, Unknown Primary
NCI ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
110.
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type
Germ Cell Tumor
NCI ID
NCT04192344
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
111.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04546399
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
112.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCI ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
113.
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type
Leukemia
NCI ID
NCT04293562
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
114.
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Cancer Type
Melanoma
NCI ID
NCT04511013
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
115.
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
116.
A Study to Compare Treatments for a Type of Kidney Cancer called TFE/Translocation Renal Cell Carcinoma (tRCC)
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT03595124
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
117.
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type
Ovarian Cancer
NCI ID
NCT04251052
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
118.
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT02773030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
119.
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03989414
Protocol IDs
CC-92480-MM-002
NCI-2019-04130
2018-004767-31
U1111-1233-5619
120.
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type
Sarcoma
NCI ID
NCT04554914
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
121.
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type
Bile Duct Cancer
NCI ID
NCT03656536
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
122.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT05581004
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
123.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Lung Cancer, Solid Tumor
NCI ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
124.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Gynecologic Cancers, Ovarian Cancer, Prostate Cancer
NCI ID
NCT04972981
Protocol IDs
ADCT-901-101
NCI-2021-10797
2021-002292-19
125.
A Study to Examine How Often (Every 5 Years or 10 Years) a Colonoscopy Should be Done in Participants Who Had One or Two Small Growths of Tissue Removed from Their Colon
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT05080673
Protocol IDs
NRG-CC005
NRG-CC005
NRG-CC005
NCI-2020-00733
126.
A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT03914625
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
127.
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04946864
Protocol IDs
APG2575XU103
NCI-2021-11630
128.
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for a Brain Tumor
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT04939597
Protocol IDs
ACCL2031
ACCL2031
COG-ACCL2031
NCI-2020-07502
129.
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).
Cancer Type
Lung Cancer
NCI ID
NCT04429087
Protocol IDs
1438-0001
NCI-2021-01392
2019-000729-31
130.
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03970447
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
131.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer
NCI ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
132.
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04380740
Protocol IDs
20-227
NCI-2022-03010
133.
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT05169567
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
134.
Abemaciclib and Letrozole to Treat Endometrial Cancer
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT04393285
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
135.
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Neuroblastoma, Sarcoma
NCI ID
NCT02644460
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
136.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
137.
Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients with Stage II-III Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03801902
Protocol IDs
Treatment Sites (4)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
138.
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT02582697
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
139.
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT03067181
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
140.
Additional Support Program via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Cancer Type
Breast Cancer
NCI ID
NCT04379570
Protocol IDs
A191901
A191901
A191901
NCI-2020-02479
141.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03391778
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
142.
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary, Urethral Cancer
NCI ID
NCT02122172
Protocol IDs
IRB13-0540
NCI-2014-00859
13-0540
143.
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03601078
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
144.
An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type
Cancer Control
NCI ID
NCT04462302
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
145.
An Internet-Based Program to Help Cancer Survivors Manage Pain, IMPACTS Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04462302
Protocol IDs
WF-1901
WF-1901
WF-1901
NCI-2020-02315
146.
An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Cancer Type
Adrenal Cancer, Neuroblastoma
NCI ID
NCT01590680
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
147.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type
Pancreatic Cancer
NCI ID
NCT04858334
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
148.
ASCO Survey on COVID-19 in Oncology (ASCO) Registry
Cancer Type
COVID-19, Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04659135
Protocol IDs
Pro00014181
NCI-2021-00737
149.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
150.
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04105010
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
151.
Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT03600701
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
152.
Atezolizumab in Treating Patients with Cancer following Adoptive Cell Transfer
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT02862275
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Atlanta
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
153.
AWAKE Mobile Application and Coaching Phone Calls in Improving Health-Promoting Behaviors in Adolescent Cancer Survivors and Their Guardians
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03564587
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
154.
AYA-RISE for the Improvement of Cancer Risk Communication and Decision-Making in Adolescents and Young Adults with Cancer Risk Syndromes
Cancer Type
Cancer-Related Syndrome
NCI ID
NCT04323774
Protocol IDs
20-003
NCI-2020-03811
155.
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCI ID
NCT04729608
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
156.
Battery Powered Drill versus Conventional Methods in Comparing Quality of Bone Marrow Biopsy, Convenience, and Pain Control in Patients with Plasma Cell Disorders
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03078452
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
157.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05208307
Protocol IDs
Winship5382-21
NCI-2021-08385
STUDY00003092
158.
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT04264702
Protocol IDs
Treatment Sites (6)
Central Georgia Cancer Care, PC - Macon
Macon
Joanne Kerr, RN, BSN, OCN
478-743-7068
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
John B Amos Cancer Center
Columbus
Courtney Dean Alexander
706-780-6201
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
159.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT05387915
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
160.
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type
Lung Cancer
NCI ID
NCT03851445
Protocol IDs
Treatment Sites (14)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
161.
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCI ID
NCT04955808
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
162.
Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT03114865
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
163.
Blue Light Cystoscopy With Cysview® Registry
Cancer Type
Bladder Cancer
NCI ID
NCT02660645
Protocol IDs
BLCCR-001
NCI-2018-00299
164.
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT05250895
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
165.
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT04258943
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
166.
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCI ID
NCT05039073
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
167.
Brentuximab Vedotin and Nivolumab in Treating Patients with Early Stage Classic Hodgkin Lymphoma
Cancer Type
Hodgkin Lymphoma
NCI ID
NCT03712202
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
168.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCI ID
NCT01896999
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
169.
Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03534804
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
170.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
171.
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT03541902
Protocol IDs
2017-0725
NCI-2018-01041
172.
Cabozantinib, Nivolumab, and Ipilimumab for the Treatment of Metastatic Non-clear Cell Renal Cell Cancer
Cancer Type
Kidney Cancer
NCI ID
NCT04413123
Protocol IDs
19-789
NCI-2020-11407
173.
Carboplatin and Paclitaxel with or without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT02876107
Protocol IDs
2016-0177
NCI-2017-00619
174.
Caris Biorepository Research Protocol
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT01499394
Protocol IDs
Treatment Sites (1)
Southeastern Urology Associates - Macon
Macon
Ginger Safford, RN
478-742-0932
175.
CAR-T Long Term Follow Up (LTFU) Study
Cancer Type
Unknown Primary
NCI ID
NCT02445222
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
176.
CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT04455750
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
177.
CD40 Agonistic Monoclonal Antibody APX005M in Treating Pediatric Patients with Recurrent or Refractory Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCI ID
NCT03389802
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
178.
Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT04428671
Protocol IDs
Winship4851-19
NCI-2019-07373
IRB00115160
179.
Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05274763
Protocol IDs
EU5492-21
NCI-2022-00233
STUDY00003563
180.
Chemoradiotherapy with or without Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer
NCI ID
NCT03775265
Protocol IDs
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
181.
Chemotherapy before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients with Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT03493425
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
182.
Childhood Cancer Survivor Study
Cancer Type
Brain & Spinal Cord Tumor, Hodgkin Lymphoma, Leukemia, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Solid Tumor
NCI ID
NCT01120353
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215
183.
CIBMTR Research Database
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT01166009
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
184.
Circulating Tumor DNA Testing in Predicting Treatment for Patients with Stage IIA Colon Cancer After Surgery, COBRA Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT04068103
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
185.
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery
Cancer Type
Brain Tumor, Liver Cancer / Hepatoblastoma
NCI ID
NCT03533582
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
186.
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type
Leukemia
NCI ID
NCT03850574
Protocol IDs
HM-FLTI-101
NCI-2019-06837
187.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT05334069
Protocol IDs
Treatment Sites (1)
Low Country Cancer Care Associates, PC
Savannah
188.
Collection and Storage of Tissue and Blood Samples from Patients with Cancer
Cancer Type
Lymphoma, Multiple Myeloma, Plasma cell neoplasm, Solid Tumor
NCI ID
NCT02474160
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
189.
Collection of Research Data and Samples from Patients Treated with Immunotherapy to Study Its Side Effects
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04242095
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
190.
Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCI ID
NCT02567435
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
191.
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCI ID
NCT02997228
Protocol IDs
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
192.
Comparing an Alternative Surgical Procedure, Sentinel Lymph Node (SLN) Biopsy, with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer
Cancer Type
Head and Neck Cancer
NCI ID
NCT04333537
Protocol IDs
NRG-HN006
NRG-HN006
NCI-2020-01542
193.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT05050162
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
194.
Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT01993810
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411